There are 2789 resources available
723MO - Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
Presenter: Ignace Vergote
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
724MO - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: David O'Malley
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Presenter: Susana Banerjee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
726MO - Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
Presenter: Nicoletta Colombo
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA34 - Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
Presenter: Joyce Liu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
795MO - Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
Presenter: David O'Malley
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Webcast
LBA49 - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Presenter: Edward Garon
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Presenter: Natasha B. Leighl
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
Presenter: Catherine A. Shu
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA50 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
Presenter: Anne-Marie Dingemans
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast